Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biopharma News
Biosimilar Deals 2025
Biosimilar Deals 2026
Biosimilars Deals 2023
Biosimilars Deals 2024
Chantal Savage
Diversity
Helen Macpherson
Intranet
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Sally Paterson
Trade Marks
Webinars

Lupin/Sandoz Launch Biosimilar Ranibizumab in Europe

Nov 12, 2026

On 12 November 2026, Lupin and Sandoz announced the launch of Ranluspec®, biosimilar to Genentech’s Lucentis® (ranibizumab), in Europe, excluding Germany.  Ranluspec® is developed, manufactured and registered by Lupin and is commercialised by Sandoz in the EU (excluding Germany) under an August 2025 agreement.

Ranluspec® was approved by the European Commission in February 2026 in vial and pre-filled syringe presentations and is indicated for the treatment of nAMD, visual impairment due to DME, proliferative diabetic retinopathy, visual impairment due to macular oedema secondary to retinal vein occlusion (RVO) and visual impairment due to choroidal neovascularisation.

Ranibizumab biosimilars already approved and launched in Europe include Samsung Bioepis’ Byooviz® (approved August 2021, commercially available since March 2023), STADA/Xbrane’s Ximluci® (launched in April 2023, following November 2022 approval), and Formycon’s Ranivisio® (approved August 2022, commercialised in by Teva).  Lupin’s Vislyfa® (ranibizumab) was recommended by the CHMP in May 2026 and approved in July 2026, while Accord’s Fovlussea® and Intas’ Rexatilux® received positive CHMP opinions in October 2026 and April 2026 (approved June 2026), respectively.